Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14 [Breast Cancer]

Conclusion For LDR, RS is strongly prognostic in patients with higher quantitative ESR1. Risk of LDR is relatively low for patients with low RS. These results suggest the value of extended tamoxifen therapy merits evaluation in patients with intermediate and high RS with higher ESR1 expression at initial diagnosis.

http://jco.ascopubs.org/cgi/content/short/34/20/2350?rss=1

Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Wolmark, Mamounas, Baehner, Butler, Tang, Jamshidian, Sing, Shak, Paik Tags: Translational Oncology Breast Cancer Source Type: research